Completed PHASE2 INTERVENTIONAL NCT00087997

A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas

Sponsor: Synta Pharmaceuticals Corp.

Interventions STA-4783

Updated 6 times since 2017 Last updated: Jun 19, 2006 Started: Jul 31, 2004 Completion: Oct 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Soft Tissue Sarcoma, this trial is completed. The trial is conducted by Synta Pharmaceuticals Corp. and has accumulated 6 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jul 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Synta Pharmaceuticals Corp.

Data source: Synta Pharmaceuticals Corp.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Atlanta, United States , Boston, United States , Charlotte, United States , Chicago, United States , Detroit, United States , Flint, United States , Gainesville, United States , Houston, United States , Los Angeles, United States and 16 more locations